9.0904

4.32% -0.3896

Oric Pharmaceuticals Inc (ORIC)

Overview News Price History Option Chain Financials Discussions Forecast

Oric Pharmaceuticals Inc stock is traded at $9.0904, with a volume of 215.97K. It is down -4.32% in the last 24 hours and down -5.62% over the past month. ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.

Previous Close:

$9.48

Open:

$9.52

24h Volume:

215.97K

Relative Volume:

0.48

Market Cap:

$648.99M

Revenue:

Net Income/Loss:

$-100.70M

P/E Ratio:

-4.1699

EPS:

-2.18

Net Cash Flow:

$-86.54M

1W Performance:

+0.78%

1M Performance:

-5.62%

6M Performance:

-6.59%

1Y Performance:

+28.11%

1-Day Range:

$8.96

$9.615

1-Week Range:

$8.71

$10.37

52-Week Range:

$5.85

$16.65

Oric Pharmaceuticals Inc Stock (ORIC) Company Profile

Name

Oric Pharmaceuticals Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(650) 388-5600

Address

240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA

Employee

107

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

ORIC's Discussions on Twitter

Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-22-23	Initiated	Wedbush	Outperform
Mar-23-23	Upgrade	H.C. Wainwright	Neutral → Buy
Mar-21-23	Upgrade	Guggenheim	Neutral → Buy
Mar-16-23	Upgrade	Oppenheimer	Perform → Outperform
Jul-18-22	Resumed	Oppenheimer	Perform
Apr-04-22	Upgrade	Citigroup	Neutral → Buy
Mar-25-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-22-22	Downgrade	Citigroup	Buy → Neutral
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Mar-22-22	Downgrade	Oppenheimer	Outperform → Perform
Jul-06-21	Upgrade	Citigroup	Neutral → Buy
Jan-25-21	Downgrade	Citigroup	Buy → Neutral
Aug-13-20	Initiated	Robert W. Baird	Outperform
Aug-06-20	Upgrade	Citigroup	Neutral → Buy
Aug-03-20	Initiated	H.C. Wainwright	Buy
May-19-20	Initiated	Citigroup	Neutral
May-19-20	Initiated	Guggenheim	Buy
May-19-20	Initiated	JP Morgan	Overweight
May-19-20	Initiated	Jefferies	Buy

View All

Oric Pharmaceuticals Inc Stock (ORIC) Latest News

Nov 04, 2024

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times

Nov 04, 2024

Nov 03, 2024

Long Term Trading Analysis for (ORIC) - Stock Traders Daily

Nov 03, 2024

Nov 01, 2024

ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Nov 01, 2024

Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Price Target at $18.00 - Defense World

Nov 01, 2024

Oct 23, 2024

ORIC-114 shows promise in preclinical cancer study By Investing.com - Investing.com Australia

Oct 23, 2024

ORIC-114 shows promise in preclinical cancer study - Investing.com

Oct 23, 2024

ORIC® Pharmaceuticals Presents Data Further Supporting - GlobeNewswire

Oct 23, 2024

ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Yahoo Finance

Oct 23, 2024

Oct 16, 2024

Analytical Overview: ORIC Pharmaceuticals Inc (ORIC)’s Ratios Tell a Financial Story - The Dwinnex

Oct 16, 2024